AIA Group Ltd Increases Stock Holdings in Gilead Sciences, Inc. $GILD

AIA Group Ltd grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 68.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,372 shares of the biopharmaceutical company’s stock after purchasing an additional 18,826 shares during the period. AIA Group Ltd’s holdings in Gilead Sciences were worth $5,147,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in GILD. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $26,000. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences during the 2nd quarter worth about $30,000. MTM Investment Management LLC increased its holdings in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 176 shares during the period. Kilter Group LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $33,000. Finally, Millstone Evans Group LLC boosted its stake in shares of Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 118 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Pipeline boost — Assembly Biosciences licensed a helicase‑primase inhibitor program (including candidates ABI‑5366 and ABI‑1179) to Gilead after positive Phase 1b interim data, adding early‑stage herpes assets to Gilead’s antiviral franchise and expanding near‑term development options. This is a clear pipeline + inorganic expansion signal. Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
• Positive Sentiment: Analyst support — Multiple firms have raised targets or maintain buy ratings (Deutsche Bank, Jefferies, BofA, Needham), lifting consensus target above the current trade and providing institutional buying ammunition. This helps underpin the shares despite short‑term weakness.
• Positive Sentiment: Shareholder return signal — Gilead recently raised its quarterly dividend to $0.82 (ann. $3.28), reinforcing cash‑flow confidence and appeal to income investors. Dividend / SEC Filing
• Neutral Sentiment: Trending attention / coverage — Zacks and other outlets flagged GILD as a trending stock; that can increase intraday volume and volatility but doesn’t indicate fundamental change. Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
• Neutral Sentiment: Market‑flow signals — Unusual options activity and recent coverage pieces on valuation have attracted attention; these can amplify swings but are ambiguous for direction until large trades or analyst revisions follow. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider selling — Recent disclosed sales (including Johanna Mercier and a reported sale by the CFO) have been highlighted in filings and press summaries; insider sales can weigh on sentiment even when they’re routine or pre‑planned. Insider Sale – Johanna Mercier CFO SEC Filing

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. The trade was a 1.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 309,280 shares of company stock valued at $44,068,850. Company insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GILD. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 target price on the stock. UBS Group boosted their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Wolfe Research increased their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Rothschild & Co Redburn raised their price objective on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Finally, Oppenheimer lifted their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences Trading Down 0.1%

GILD opened at $141.11 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The business’s 50 day moving average is $142.36 and its two-hundred day moving average is $127.60. The firm has a market cap of $175.18 billion, a price-to-earnings ratio of 20.84, a price-to-earnings-growth ratio of 1.85 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the firm posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.